Laboratory Aspects of Using the Results of NT-Probnp Concentration Immunochemical Determination in the Management of Patients With Heart Failure: Support For Clinical Decision-Making

The burden of heart failure (HF) has been increasing worldwide in recent decades. Early diagnosis of HF based on the outpatient measurement of natriuretic peptide (NP) concentration will allow timely initiation of the treatment and reducing the incidence of adverse outcomes in HF. Unfortunately, the frequency of NP testing remains low worldwide. At the online expert meeting held on March 15, 2024, the features of the N-terminal pro-brain natriuretic peptide (NT-proBNP) test (Elecsys proBNP by Roche) were discussed along with the interpretation of test results and presentation of results in laboratory reports. The experts addressed the features of the Elecsys proBNP test in patients with suspected HF in various clinical scenarios (chronic and acute HF). The limits of clinical decision for the NT-proBNP test were established depending on the clinical scenario. Changes in the Elecsys proBNP test results depending on the comorbidities were addressed. The experts suggested ways to optimize the format of the Elecsys proBNP test result reports in the Russian Federation, which will accelerate the implementation of the test in clinical practice and optimize the management of HF patients.

1. Polyakov D.S., Fomin I.V., Belenkov Yu.N., Mareev V.Yu., Ageev F.T., Artemjeva E.G. et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021;61(4):4–14. DOI: 10.18087/cardio.2021.4.n1628

2. Shlyakhto E.V., Belenkov Yu.N., Boytsov S.A., Villevalde S.V., Galyavich A.S., Glezer M.G. et al. Interim analysis of a prospective observational multicenter registry study of patients with chronic heart failure in the Russian Federation ‘PRIORITET-CHF’: initial characteristics and treatment of the first included patients. Russian Journal of Cardiology. 2023;28(10):93–103. DOI: 10.15829/1560-4071-2023-5593

3. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42(36):3599–726. DOI: 10.1093/eurheartj/ehab368

4. Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N et al. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. Journal of Cardiac Failure. 2021;27(4):387–413. DOI: 10.1016/j.cardfail.2021.01.022

5. Mamas MA, Sperrin M, Watson MC, Coutts A, Wilde K, Burton C et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. European Journal of Heart Failure. 2017;19(9):1095–104. DOI: 10.1002/ejhf.822

6. Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Pedro Ferreira J, Zannad F et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. The Lancet. 2020;396(10244):121–8. DOI: 10.1016/S0140-6736(20)30748-0

7. Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nature Reviews Cardiology. 2020;17(12):761–72. DOI: 10.1038/s41569-020-0406-8

8. Scheen AJ. Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology. 2020;16(10):556–77. DOI: 10.1038/s41574-020-0392-2

9. Tereshchenko S.N., Galyavich A.S., Uskach T.M., Ageev F.T., Arutyunov G.P., Begrambekova Yu.L. et al. 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):311–74. DOI: 10.15829/1560-4071-2020-4083

10. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895–1032. DOI: 10.1161/CIR.0000000000001063

11. Jones GRD, Legg M. Report formatting in laboratory medicine – a call for harmony. Clinical Chemistry and Laboratory Medicine. 2018;57(1):61–5. DOI: 10.1515/cclm-2017-1165

12. Voskanyan Yu.E. The safety of patients and related unfavorable occurrences in medicine: the systematic review. Problems of Social Hygiene Public Health and History of Medicine. 2019;27(4):408–13. DOI: 10.32687/0869-866X-2019-27-4-408-413

13. Guidelines for the diagnosis of heart failure. European Heart Journal. 1995;16(6):741–51. DOI: 10.1093/oxfordjournals.eurheartj.a060992

14. Bayes-Genis A, Docherty KF, Petrie MC, Januzzi JL, Mueller C, Anderson L et al. Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: A clinical consensus statement from the Heart Failure Association of the ESC. European Journal of Heart Failure. 2023;25(11):1891–8. DOI: 10.1002/ejhf.3036

15. Ministry of Health of the Russian Federation. Order from 20.04.2022 № 272n “On approval of the standard of medical care for adults with chronic heart failure (diagnosis, treatment and follow-up)”. Av. at: http://publication.pravo.gov.ru/Document/View/0001202206020034?index=4. 2022.

16. Ministry of Health of the Russian Federation. Order from 15.03.2022 № 168n “On approval of the procedure for conducting dispensary observation of adults” (with amendments and additions). Av. at: https://base.garant.ru/404523658/.

17. Talha KM, Januzzi JL, Meng T, Greene SJ, Vaduganathan M, Janicijevic TK et al. Use of natriuretic peptides and echocardiography for diagnosing heart failure. European Journal of Heart Failure. 2024;26(3):551–60. DOI: 10.1002/ejhf.3165

18. Protopapa K, Juniper M, Koomson D, Smith N. Failure to function: a report on acute heart failure. British Journal of Hospital Medicine. 2019;80(7):366–7. DOI: 10.12968/hmed.2019.80.7.366

19. Registration certificate of Roszdravnadzor № RZN 2021/14423 from 27.05.2021. Av. at: https://goszdravnadzor.ru/ru-roszdravnadzora-№-rzn-2021-14423-ot-27-maya-2021-goda/?ysclid=lyhcojogcj963915413.

20. FDA. 510(k) Premarket Notification. Number: K032646 ELECSYS PROBNP IMMUNOASSAY. [Internet] Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K032646

21. Januzzi JL, Chen-Tournoux AA, Christenson RH, Doros G, Hollander JE, Levy PD et al. N-Terminal Pro–B-Type Natriuretic Peptide in the Emergency Department: The ICON-RELOADED Study. Journal of the American College of Cardiology. 2018;71(11):1191–200. DOI: 10.1016/j.jacc.2018.01.021

22. Lilley CM, Mirza KM. Critical role of pathology and laboratory medicine in the conversation surrounding access to healthcare. Journal of Medical Ethics. 2023;49(2):148–52. DOI: 10.1136/medethics-2021-107251

23. Ministry of Health of Russian Federation. Order from 18.05.2021 № 464n “On approval of the Rules for conducting laboratory tests”. Av. at: http://publication.pravo.gov.ru/Document/View/0001202106010055.

24. BNP, NT-proBNP, and MR-proANP Assays: Analytical Characteristics Designated By Manufacturer IFCC Committee on Clinical Applications of Cardiac Bio-Makers (C-CB) v062024. Av. at: https://pub-180a8d00f517477ba49634e6b2b147e3.r2.dev/2024/03/BNP-NT-proBNP-and-MR-proANP-Assays-Analytical-Characteristics-Designated-By-Manufacturer-v062024.pdf.

25. GOST R 53022.3-2008. Clinical laboratory technologies. Requirements for the quality of clinical laboratory tests. Part 3. Assessment of laboratory tests clinical significance. Av. at: https://protect.gost.ru/document1.aspx?control=31&baseC=6&page=0&month=8&year=2009&search=&id=174413.

26. Johns Hopkins Department of Pathology Core Laboratory Reference Ranges. Av. at: https://pathology.jhu.edu/build/assets/department/files/Core-Lab-Reference-Ranges.pdf.

27. INVITRO. Study of Natriuretic hormone (B-type) N-terminal propeptide (NT-proBNP, N-Terminal Pro-brain Natriuretic Peptide, Pro-B-Type Natriuretic Peptide). Av. at: https://www.invitro.ru/analizes/for-doctors/492/17958/.

28. Labor Berlin. Noradrenalin im Urin. Av. at: https://www.laborberlin.com/unsere-leistungen/leistungsverzeichnis-detail/?id=292$$.

29. KDL. Study of N-terminal fragment of B-type natriuretic propeptide (NT-proBNP). Av. at: https://kdl.ru/analizy-i-tseny/n-kontsevoy-fragment-natriyureticheskogo-propeptida-v-tipa-nt-probnp.

30. Zaphiriou A, Robb S, Murray-Thomas T, Mendez G, Fox K, McDonagh T et al. The diagnostic accuracy of plasma BNP and NT-pro BNP in patients referred from primary care with suspected heart failure: Results of the UK natriuretic peptide study. European Journal of Heart Failure. 2005;7(4):537–41. DOI: 10.1016/j.ejheart.2005.01.022

31. Betti I, Castelli G, Barchielli A, Beligni C, Boscherini V, De Luca L et al. The Role of N-terminal PRO-Brain Natriuretic Peptide and Echocardiography for Screening Asymptomatic Left Ventricular Dysfunction in a Population at High Risk for Heart Failure. The PROBE-HF Study. Journal of Cardiac Failure. 2009;15(5):377–84. DOI: 10.1016/j.cardfail.2008.12.002

32. Nogi K, Yamamoto R, Ueda T, Nogi M, Ishihara S, Nakada Y et al. Derivation and validation of a clinical predictive model of NT-pro-BNP ≥125 pg/mL to detect pre-heart failure. Journal of Cardiology. 2023;82(6):481–9. DOI: 10.1016/j.jjcc.2023.05.011

33. Gustafsson F, Steensgaard-Hansen F, Badskjær J, Poulsen AH, Corell P, Hildebrandt P. Diagnostic and Prognostic Performance of N-Terminal ProBNP in Primary Care Patients With Suspected Heart Failure. Journal of Cardiac Failure. 2005;11(5):S15–20. DOI: 10.1016/j.cardfail.2005.04.022

34. Hildebrandt P, Collinson PO, Doughty RN, Fuat A, Gaze DC, Gustafsson F et al. Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary care. European Heart Journal. 2010;31(15):1881–9. DOI: 10.1093/eurheartj/ehq163

35. Mu S, Echouffo-Tcheugui JB, Ndumele CE, Coresh J, Juraschek S, Brady T et al. NT-pro BNP Reference Intervals in Healthy U.S. Children, Adolescents, and Adults. The Journal of Applied Laboratory Medicine. 2023;8(4):700–12. DOI: 10.1093/jalm/jfad024

36. Patel N, Gutiérrez OM, Arora G, Howard G, Howard VJ, Judd SE et al. Race-based demographic, anthropometric and clinical correlates of N-terminal-pro B-type natriuretic peptide. International Journal of Cardiology. 2019;286:145–51. DOI: 10.1016/j.ijcard.2019.02.034

37. Suthahar N, Meijers WC, Ho JE, Gansevoort RT, Voors AA, Van Der Meer P et al. Sex-specific associations of obesity and N-terminal pro-B-type natriuretic peptide levels in the general population. European Journal of Heart Failure. 2018;20(8):1205–14. DOI: 10.1002/ejhf.1209

38. Ozkan B, Grams ME, Coresh J, McEvoy JW, Echouffo-Tcheugui JB, Mu SZ et al. Associations of N-terminal pro-B-type natriuretic peptide, estimated glomerular filtration rate, and mortality in US adults. American Heart Journal. 2023;264:49–58. DOI: 10.1016/j.ahj.2023.05.014

39. Ezekowitz JA, Alemayehu W, Rathwell S, Grant AD, Fiuzat M, Whellan DJ et al. The influence of comorbidities on achieving an N-terminal pro-b-type natriuretic peptide target: a secondary analysis of the GUIDE-IT trial. ESC Heart Failure. 2022;9(1):77–86. DOI: 10.1002/ehf2.13692

40. Song BG, Jeon ES, Kim YH, Kang MK, Doh JH, Kim PH et al. Correlation Between Levels of N-terminal Pro-B-Type Natriuretic Peptide and Degrees of Heart Failure. The Korean Journal of Internal Medicine. 2005;20(1):26–32. DOI: 10.3904/kjim.2005.20.1.26

41. Januzzi JL, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. The American Journal of Cardiology. 2005;95(8):948–54. DOI: 10.1016/j.amjcard.2004.12.032

42. Januzzi JL, van Kimmenade R, Lainchbury J, Bayés-Genis A, Ordoñez-llanos J, Santaló-Bel M et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: The International Collaborative of NT-proBNP Study. European Heart Journal. 2005;27(3):330–7. DOI: 10.1093/eurheartj/ehi631

43. Pfister R, Tan D, Thekkanal J, Erdmann E, Schneider C. Predictive value of NT-pro-BNP for the non-cardiologist. A study on 573 hospitalized patients with cardiovascular disease. Deutsche Medizinische Wochenschrift. 2008;133(12):564–9. DOI: 10.1055/s-2008-1067282

44. Singh S, Pandey A, Neeland IJ. Diagnostic and prognostic considerations for use of natriuretic peptides in obese patients with heart failure. Progress in Cardiovascular Diseases. 2020;63(5):649–55. DOI: 10.1016/j.pcad.2020.09.006

45. Bhatt AS, Cooper LB, Ambrosy AP, Clare RM, Coles A, Joyce E et al. Interaction of Body Mass Index on the Association Between N-Terminal-Pro-b-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). Journal of the American Heart Association. 2018;7(3):e006740. DOI: 10.1161/JAHA.117.006740

46. DeFilippi C, Van Kimmenade RRJ, Pinto YM. Amino-Terminal Pro– B-Type Natriuretic Peptide Testing in Renal Disease. The American Journal of Cardiology. 2008;101(3A):S82–8. DOI: 10.1016/j.amjcard.2007.11.029

47. Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R et al. Renal Function, Congestive Heart Failure, and Amino-Terminal Pro-Brain Natriuretic Peptide Measurement: Results From the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. Journal of the American College of Cardiology. 2006;47(1):91–7. DOI: 10.1016/j.jacc.2005.08.051

48. Tsutsui H, Albert NM, Coats AJS, Anker SD, Bayes-Genis A, Butler J et al. Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society. European Journal of Heart Failure. 2023;25(5):616–31. DOI: 10.1002/ejhf.2848

49. Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E et al. How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal. 2019;40(40):3297–317. DOI: 10.1093/eurheartj/ehz641

50. Van Doorn S, Geersing G-J, Kievit RF, Van Mourik Y, Bertens LC, Van Riet EES et al. Opportunistic screening for heart failure with natriuretic peptides in patients with atrial fibrillation: a meta-analysis of individual participant data of four screening studies. Heart. 2018;104(15):1236–7. DOI: 10.1136/heartjnl-2017-312781

51. GOST R ISO 15189-2015. Medical laboratories. Particular requirements for quality and competence. Av. at: https://protect.gost.ru/default.aspx/document1.aspx?control=31&baseC=6&page=2&month=11&year=2015&search=&id=200121.